HAMP and anemia (phenotype): Tocilizumab improved anemia of inflammation in MCD accompanied by down-regulation of hepcidin, suggesting that IL-6 plays an essential role in the induction of hepcidin in MCD, although multiple factors can affect serum hepcidin levels [16].